Cansino Biotech (06185): 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin) approved for clinical trials in China

Zhitongcaijing · 01/05 09:01

Zhitong Finance App News, Cansino Biotech (06185) announced that the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/ tetanus toxin) (PCV24) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials.

The company's PCV24 covers the main popular serotypes of pneumococci at present. It uses a covalent combination of polysaccharide antigen with protein carriers and dual carrier technology. It is intended to be suitable for vaccination of people aged 2 months (minimum 6 weeks) to prevent infectious diseases caused by 24 pneumococcal serotypes. The product completed the development and confirmation of 24 serotype purified polysaccharides, polysaccharide protein conjugate stock solution production processes, and finished product prescriptions. As of the date of this announcement, the 24-valent pneumococcal polysaccharide conjugate vaccine was not marketed at home or abroad.